Referencer til "Psykofarmaka til ældre med delir eller demens"

Fra Rationel Farmakoterapi nr. 1 2006

1. Larsen, L, Petersen, I I. Får svage ældre for meget psykofarmaka? Gerontologi og Samfund 2004; 20: 57-9.
2. Embedslægeinstitutionen for Vestsjællands Amt. Brug af medicin på plejehjem. 2004. www.eli.dk.
3. Lægemiddelstyrelsen. Forbrug af antipsykotiske lægemidler i Danmark blandt ældre. 2005. www.Laegemiddelstyrelsen.dk.
4. Gulmann N C. Ethical aspects of psychotropic drugs in dementia. I: Workshop (red): Treatment of mental condition in patients with dementia. Uppsala: Swedish and Norwegian medical control authorities. 1995; 163-74.
5. Cooper J K. Drug treatment of Alzheimer's disease. Arch Int Med 1991; 151: 245-9.
6. Chief Medical Officer. Current problems in pharmacology. Committee for Safety of Medicines Update. London, United Kingdom: Department of Health; May 20-6, 1994.
7. Sundhedsstyrelsen. Psykofarmakaforbrug på plejehjem. Redegørelse. ISBN 87-503-92557. København: Staugaard Jensen, 1991.
8. Sundhedsstyrelsen. Vejledning om behandling med antidepressiva. Vejledning om behandling med antipsykotika. Købernhavn: Schultz Information, 2004: 44-6.
9. Sundhedsstyrelsen. Sundhedsstyrelsen indskærper landets læger at udvise stor forsigtighed ved behandling med antipsykotika til ældre patienter med demens. Ugeskr Læger 2004; 166: 1395.
10. Sundhedsstyrelsen. Forbruget af antipsykotiske lægemidler blandt ældre. Rapport fra arbejdsgruppe nedsat af Sundhedsstyrelsen 2004. www.sundhedsstyrelsen.dk.
    
11. Shorr R I, Fought R L, Ray W A. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA. 1994; 271: 358-62.
12. Sørensen L, Foldspang A, Gulmann N C, Munk-Jøgensen P. Determinants for the use for psychotropics among nursing home residents. Int J Geriatr Psychiatry 2001; 16: 147-54.
13. Gulmann N C. Uhensigtsmæssig psykofarmakologisk behandling af ældre. En årsopgørelse. Ugeskr Læger 1993; 155: 714-8.
14. Workgroups on delirium. American Psychiatric Association. Practical guidelines for treatment of patients with delirium. Am J Psychiatry 1999; 156: 1-20.
15. Burns A, Gallagley A, Byrne J.  Delirium. J Neurol Neurosurg Psychiatry 2004; 75: 362-7.
16. Weber J B, Coverdale J H, Kunik M E.  Delirium: current trends in prevention and treatment. Intern Med J 2004; 34: 115-21.
17. Breitbart W, Marotta R, Platt M M et al. A double-blind trial of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153: 231-7.
18. Expert Consensus Panel. Using antipsychotic agents in older patient. J Clin Psychiatry 2004; 65 (Suppl 2): 5-41.
19. Finkel S I. (ed). Behavioral and psychological signs and symptoms of dementia: Implications for research and treatment. Int Psychogeriatrics 1996: 8 (Suppl 3): 215-552.
20. Furniss L, Craig S K, Burns A. Medication use i nursing homes for elderly people. Int J Geriatr Psychiatry 1998; 13: 433-9.
21. McGrath A M, Jackson G A. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. Brit Med J 1996; 312: 611-2.
22. Ballard C. O'Brien J, James I et al. Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symtoms, language skills, and psychotropic drugs. Int Psychogeriatr 2001; 13: 93-106.
23. Findlay D, Sharma J, McEwen J et al. Double-blind controlled withdrawal of thioridazine treatment in elderly female inpatients with senile dementia. Int J Geriatr Psychiatry 1989; 4: 115-20.
24. Cohen-Mansfield J, Lipson S, Werner P et al. Withdrawal of haloperidol, thioridazine and lorazepam in the nursing home: A controlled, double-blind study. Arch Intern Med 1999; 159: 1733-40.
25. van Reekum R, Clarke D, Conn D et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr 2002; 14: 197-210.
26. Ballard C G, Margallo-Lana M L. The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. J Clin Psychiatry 2004; 65 (suppl 11): 23-8.
27. Hartikainen S, Rahkonen T, Kautiainen H, Sulkava R. The use of psychotropics and survival in demented elderly individuals. Int Clin Psychopharmacol 2005; 20: 227-31.
28. Weiner D K, Hanlon J T, Studenski S A. Effects of central nervous system polypharmacy on falls liability in community-dwelling elderly. Gerontology 1998; 44: 217-21.
29. Thapa P B, Gideon P, Fought R L, Ray W A. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995; 142: 202-11.
30. Paterniti S, Dufouil C, Bisserbe J C, Alperovitch A. Anxiety, depression, psychotropic drug use and cognitive impairment. Psychol Med 1999; 29: 421-8.
31. Lee P E, Gill S S, Freedman M, Bronshill S E, Hillmer M P, Rochon P A. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia; systematic review. Brit Med J 2004: Online First bmj.com.
32. Schneider L S, Dagerman K S, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943.
33. Sink K M, Holden K F, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A Review of the Evidence. JAMA 2005; 293: 596-608.
34. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; 2: CD002852.
35. Jeste D V, Lacro J P, Bailey A et al. Lower incidense of tardiv dyskinesia with risperidon compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716-9.
36. De Deyn R P, Rabheru K, Rasmusen A et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55.
37. Katz I R, Jeste D V, Mintzer J E et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized double-blind trial. J Clin Psychiatry 1999; 60: 107-15.
38. Street J S, Clark S, Gannon K S et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimers disease in nursing care facilities. A double-blind randomized placebo-controlled trial. Arch Gen Psychiatry 2000; 57: 968-76.
39. Stephen P J, Williamson J. Drug-induced Parkinsonism in the elderly. Lancet 1984; 202: 1082-3.
40. Casey D E. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacology 1995; 10 (suppl 3): 105-14.
41. Lyketsos C G, DelCampo L, Steinberg M et al. Depression in Alzheimer disease. Arch Gen Psychiatry 2003; 60: 737-46.
42. Nyth A L, Gottfries C G. The Clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Brit J Psychiatry 1990; 157: 894-901.
43. Pollock B G, Mulsant B H, Rosen et al. Comparison of citalopram, perphanazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159: 460-5.
44. Madhusoodanan S, Bogunovic O J, Moise D et al. Hyponatraemia associated with psychotropic medications. Adv Drug React Toxicol Rev 2002; 21: 17-29.
45. Institut for Rationel Farmakoterapi. Benzodiazepiner. Hvad er rationel farmakoterapi? Rationel Farmakoterapi 2004; nr. 9.
46. Tariot P N, Erb R, Podgorski A et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61.
47. Trinh N H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptms and functional impairment in Alzheimer disease. A Meta-analysis. JAMA 2003; 289: 210-6.
48. Gulmann N C. Den adfærdsforstyrrede demente patient. Månedsskr Prakt Lægegern 2005; 83: 541-51.